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The fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) mutation is associated with a high
relapse rate for patients with acute myeloid leukemia (AML) even after allogeneic hematopoietic stem cell
transplantation (HSCT). Sorafenib is a tyrosine kinase inhibitor, which inhibits the FLT3 tyrosine kinase and
has shown encouraging activity in FLT3-ITD AML. We conducted a phase I trial of maintenance sorafenib after
HSCT in patients with FLT3-ITD AML (ClinicalTrials.gov NCT01398501). Patients received a variety of condi-
tioning regimens and graft sources. A dose escalation 3 þ 3 cohort design was used to deﬁne the maximum
tolerated dose (MTD), with an additional 10 patients treated at the MTD. Sorafenib was initiated between
days 45 and 120 after HSCT and continued for 12 28-day cycles. Twenty-two patients were enrolled (status at
HSCT: ﬁrst complete remission [CR1], n ¼ 16; second complete remission [CR2], n ¼ 3; refractory, n ¼ 3). The
MTD was established at 400 mg twice daily with 1 dose-limiting toxicity (DLT) observed (pericardial effu-
sion). Two patients died of transplantation-related causes, both unrelated to sorafenib. Two patients stopped
sorafenib after relapse and 5 stopped because of attributable toxicities after the DLT period. Median follow-up
for surviving patients is 16.7 months after HSCT (range, 8.1 to 35.0). There was 1 case of grade II acute graft-
versus-host disease (GVHD) after starting sorafenib and the 12-month cumulative incidence of chronic GVHD
was 38% (90% conﬁdence interval [CI], 21% to 56%). For all patients, 1-year progression-free survival (PFS) was
85% (90% CI, 66% to 94%) and 1-year overall survival (OS) was 95% (90% CI, 79% to 99%) after HSCT. For patients
in CR1/CR2 before HSCT (n ¼ 19), 1-year PFS was 95% (90% CI, 76% to 99%) and 1-year OS was 100%, with only
1 patient who relapsed. Sorafenib is safe after HSCT for FLT3-ITD AML and merits further investigation for the
prevention of relapse.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Fms-like tyrosine kinase 3 internal tandem duplication
(FLT3-ITD) mutations are found in approximately one
quarter of patients with acute myeloid leukemia (AML) [1-3].edgments on page 2047.
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ty for Blood and Marrow Transplantation.Although initial remission rates are comparable for patients
with FLT3-ITD relative to FLT3-wildtype, patients with a
FLT3-ITD mutation are signiﬁcantly more likely to relapse
and do so more rapidly. Upon relapse, disease is often re-
fractory to further treatment.
There is no accepted optimal treatment for patients with
FLT3-ITDAML [4,5]. No randomized prospective clinical trials
have ever been conducted to conﬁrm a beneﬁt for allogeneic
HSCT in ﬁrst remission (CR1). Although a few retrospective
studies have suggested that there is no beneﬁt for allogeneic
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cated an advantage for early HSCT [8-13]. These analyses
have reported a durable disease-free survival after HSCT
ranging from 19% to 58% [7,9,12,13]. Therefore, allogeneic
HSCT has become the standard of care at many institutions
for patients with FLT3-ITD AML in CR1; however, relapse
remains the main obstacle to long-term survival.
Given the success of tyrosine kinase inhibitors incorpo-
rated into the standard treatment of chronic myeloid leu-
kemia (CML) and Philadelphia chromosomeepositive acute
lymphoblastic leukemia, several inhibitors of the FLT3 tyro-
sine kinase have been studied in recent years. These include
sorafenib, lestaurtinib (CEP-701), midostaurin (PKC412), and
quizartinib (AC220) [14-20]. The ideal time to incorporate
FLT3 inhibitors into the treatment of FLT3-ITD AML remains
unclear, although evidence based on the kinetics of endog-
enous levels of FLT3 ligand suggests that maintenance may
be optimal [21]. As very little data have been published on
using sorafenib after HSCT and before frank relapse, we
conducted a phase I study investigating sorafenib as main-
tenance therapy after allogeneic HSCT for patients with FLT3-
ITD AML.METHODS
Patients
This study was approved by the institutional review board at the Dana-
Farber Harvard Cancer Center and conducted at Dana-Farber Brigham and
Women’s Cancer Center and Massachusetts General Hospital Cancer Center.
Informed consent was obtained from all patients. This trial was registered at
ClinicalTrials.gov (NCT01398501). Patients were between the ages of 18 and
75, had a diagnosis of AML with a FLT3-ITD mutation, underwent ﬁrst
allogeneic HSCT, and had an Eastern Cooperative Oncology Group perfor-
mance status score of 0 to 2. Any conditioning regimen and graft-versus-
host disease (GVHD) prophylaxis regimen was allowed and left at the
discretion of the treating physician. Donors were 7/8 or 8/8 HLA-matched
related or unrelated, double umbilical cord blood, or haploidentical. Stem
cell sources were peripheral blood or bone marrow grafts. No pre-HSCT
disease status was speciﬁed, but patients were only eligible if they were
in morphological complete remission by bone marrow biopsy assessment
after day þ30 and if they had all cell peripheral blood chimerism  70% of
donor origin. Participants had recovered hematopoietic function deﬁned by
absolute neutrophil count  1000/mL without growth factor support in the
previous 7 days and platelet count 50,000/mL without transfusion support
in the previous 7 days. Patients with recent signiﬁcant bleeding events,
uncontrolled hypertension, serious nonhealing wounds, and active GVHD
requiring  .5 mg/kg/day of prednisone (or equivalent) or therapy beyond
systemic corticosteroids were excluded. Use of sorafenib or other FLT3 in-
hibitors before HSCT was allowed.Treatment
Sorafenib was started between 45 and 120 days after HSCT to allow for
variable recovery from the conditioning regimen and other toxicities. Sor-
afenib was given daily in 28-day cycles by continuous dosing. Patients were
assigned a ﬁxed dose based on cohort with no dose escalations allowed, and
dose interruptions and reductions deﬁned below. Patients were seenweekly
during the ﬁrst cycle to assess for toxicity and to collect correlative studies.
Patients were then evaluated monthly within the ﬁrst week of each sub-
sequent cycle. After completion of 12 cycles of therapy, continuation of
sorafenib was allowed at the discretion of the treating physician.Correlative Studies
Correlative studies were performed to analyze pharmacokinetic and
pharmacodynamic effects of sorafenib in the HSCT patient population.
Whole blood from patients at designated time points was collected into
heparinized vacuum tubes. The samples were centrifuged and the plasma
was stored frozen while awaiting analysis and then they were shipped in
batches to the reference laboratory at Johns Hopkins University. Three as-
says were performed on each sample: the plasma inhibitory activity (PIA)
assay for FLT3, FLT3 ligand concentration, and sorafenib concentration as
described [22]. PIA data take into account protein binding, active metabolite
levels, and cytokine levels, which may inﬂuence target sensitivity to
inhibition.Statistical Methods
A standard 3 þ 3study design was used with the primary endpoint to
determine the maximum tolerated dose (MTD) of sorafenib in the post-
HSCT setting. Three escalating doses of sorafenib were used: 200 mg by
mouth (PO) twice daily (BID) (dose level 1), 400 mg PO every morning/
200 mg PO every evening (dose level 2), and 400 mg PO BID (dose level 3).
The period of dose-limiting toxicity (DLT) evaluation was the ﬁrst 28-day
cycle. Patients were considered not evaluable for the determination of
MTD if they were removed from the study for reasons unrelated to therapy
or died within 28 days of starting treatment without developing a DLT and
the cause of death was unrelated to sorafenib. Any occurrence of NCI
Common Terminology Criteria for Adverse Events grade 3 or 4 adverse event
(AE) mandated temporary hold of sorafenibwith investigation conducted as
to etiology of the AE. DLT was deﬁned as drug-related AE that did not resolve
to grade or less in 14 days or recurs after resuming sorafenib. Exceptions
included grade 3 nausea, vomiting, or diarrhea that lasted < 48 hours and
responded to medical intervention or grade 3 hypertension that responded
to medical therapy. Lastly, hematological DLTs only included grade 4 neu-
tropenia or thrombocytopenia. Dose reductions were undertaken for
recurrent AEs or if the AE required > 14 days to resolve without any other
explanation. Only 2 dose reductions were allowed per participant and the
lowest dose allowed was 200 mg daily. After the MTD was established, an
additional 10 patients were treated at the MTD. Secondary endpoints
included progression-free survival (PFS), overall survival (OS), and cumu-
lative incidence rates of acute and chronic GVHD.
PFS and OS were estimated using the Kaplan-Meier method. PFS was
calculated from the date of transplantation to disease progression or death
from any cause. Patients who were alive without relapse or progression
were censored at the time of last clinical evaluation. OS was calculated
from the date of transplantation to death or censored at last clinical
evaluation. Incidence of acute GVHD before and after the start of sorafenib
was reported. The cumulative incidence of chronic GVHD (all events
occurred after the start of sorafenib) was estimated with relapse or death
as competing risks.
RESULTS
Patients
Twenty-two patients were enrolled with clinical charac-
teristics shown in Table 1. The median age was 54 years
(range, 20 to 67) with 6 patients older than 60. Three patients
were in second complete remission (CR2) and 16 patients
were in CR1 at the time of HSCT. Three patients were clas-
siﬁed as having primary refractory disease, although 2 of
them had achieved < 5% bone marrow blasts before HSCT
through the use of salvage single-agent sorafenib. The third
patient was aplastic after conventional reinduction chemo-
therapy without evidence of hematopoietic recovery. One
additional patient received sorafenib before HSCT as part of a
clinical trial combining sorafenib with conventional induc-
tion chemotherapy. In total, 3 of the 22 patients received
sorafenib before HSCT and no other patients were treated
with any other FLT3 inhibitors. Fifteen patients had a normal
karyotype and 12 patients had a concurrent nucleophosmin1
mutation. Twelve patients underwent myeloablative condi-
tioning and 10 patients were treated with reduced-intensity
conditioning. Nineteen patients received grafts from HLA-
matched related or unrelated donors (2 bone marrow and
17 peripheral blood stem cells). One patient each received
grafts from a single antigenemismatched unrelated donor,
double umbilical cord blood, and haploidentical bone
marrow, respectively.
Toxicity/GVHD
The median day of starting sorafenib was 69.5 days after
HSCT (range, 46 to 112). Three patients were treated on the
ﬁrst cohort (200 mg BID), 3 patients on the second cohort
(400 mg every morning/200 mg every evening), and 6 pa-
tients on the third cohort (400 mg BID). One DLT was
observed at the 400 mg BID dose. This was a pericardial
effusion that on subsequent evaluation was deemed unlikely
to be related to sorafenib. The MTD, based on the initial
Table 1
Clinical Characteristics (n ¼ 22)
Age Karyotype FLT3 NPM1 Disease Status Conditioning Regimen Donor Type GVHD ppx Outcome
54 Normal ITD Mutant Refractory* CyTBI MUD Tac/Mtx Died (Relapse)
20 Normal ITD WT Refractory* BuCy MUD CsA/Mtx Died (Relapse)
54 þ8 ITD Mutant Refractoryy CyTBI MRD Tac/Mtx Died (NRM)
62 t(1;14) ITD Mutant CR2 BuFlu (RIC) MUD Tac/Mtx Alive (CR)
35 Normal ITD Mutant CR2 Flu/Mel/TBI dUCB Tac/Siro Alive (CR)
49 þ6p, -21 ITD WT CR2 BuCy MUD Tac/Mtx Alive (CR)
21 Normal ITD Unknown CR1 BuCy MUD Tac/Mtx/ATG Alive (CR)
54 Normal ITD Mutant CR1 CyTBI MRD Tac/Mtx Alive (CR)
49 Normal ITD Mutant CR1 BuCy MUD Tac/Mtx/ATG Alive (CR)
42 Normal ITD Mutant CR1 CyTBI MUD Tac/Mtx Alive (CR)
62 Normal ITD Mutant CR1 BuFlu (RIC) MUD Tac/Siro/Mtx Alive (CR)
58 Normal ITD WT CR1 BuClo (RIC) MRD Tac/Mtx Alive (CR)
53 þ8 ITD Unknown CR1 FluMel (RIC) MRD Tac/Mtx Alive (CR)
67 Normal ITD WT CR1 FluCyTBI (RIC) Haplo Cy/Tac/MMF Alive (CR)
59 Normal ITD Mutant CR1 BuClo (RIC) MRD Tac/Mtx Alive (CR)
34 Normal ITD WT CR1 BuCy MRD Tac/Mtx Alive (Relapsed)
40 Normal ITD Mutant CR1 BuCy MUD Tac/Mtx Alive (CR)
65 Unknown ITD Mutant CR1 BuClo (RIC) MUD Tac/Mtx Alive (CR)
54 Normal ITD WT CR1 BuCy MRD Tac/Mtx Alive (CR)
50 t(2;3) ITD WT CR1 BuCy MUD Tac/Mtx Alive (CR)
62 þ11 ITD WT CR1 BuFlu (RIC) MMUD Tac/Mtx/ATG Alive (CR)
63 Normal ITD Mutant CR1 BuFlu (RIC) MRD Tac/Mtx Alive (CR)
NPM1 indicates nucleophosmin 1; ppx, prophylaxis; Cy, cyclophosphamide; TBI, total body irradiation; MUD, matched unrelated donor; Tac, tacrolimus; Mtx,
methotrexate; WT, wild type; Bu, busulfan; CsA, cyclosporine; MRD, matched related donor; NRM, nonrelapse mortality; t, translocation; Flu, ﬂudarabine; RIC,
reduced-intensity conditioning; Mel, melphalan; dUCB, double umbilical cord blood; Siro, sirolimus; ATG, antithymocyte globulin; Clo, clofarabine; Haplo,
haploidentical; MMF, mycophenolate mofetil; MMUD, mismatched unrelated donor.
* Achieved < 5% bone marrow blasts with sorafenib before HSCT.
y In bone marrow aplasia after reinduction chemotherapy.
Table 2
Clinically Signiﬁcant Toxicities* Encountered (n ¼ 22 Patients)
Toxicity Grade 2 Grade 3 Grade 4 Total (2-4)
Rash 4 4 0 8
Diarrhea 6 1 0 7
Anemia 1 5 0 6
Nausea 4 1 0 5
Thrombocytopenia 3 2 0 5
Weight loss 3 2 0 5
Abdominal pain 1 3 0 4
Hypertension 1 3 0 4
Anorexia 3 0 0 3
Arthralgia/myalgias 4 1 0 3
Fatigue 3 0 0 3
Leukopenia 1 1 1 3
Transaminitis 2 1 0 3
Dyspnea 2 0 0 2
Hand-foot 2 0 0 2
Headache 1 1 0 2
Sensory neuropathy 2 0 0 2
Pericardial effusion 0 0 1 1
Vomiting 1 0 0 1
* Common Terminology Criteria for Adverse Events version 4.3, grades 2
to 4.
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tional patients were then treated at the 400 mg BID dose,
making a total of 16 patients treated at the 400 mg BID dose.
Nine patients ﬁnished the planned 12 cycles of therapy and 3
patients remain on active therapy, all of whom have been on
sorafenib therapy for at least 6 cycles. Five patients stopped
sorafenib because of causes unrelated to sorafenib, including
2 cases of relapsed AML, 1 case of nephrotic syndrome,1 case
of graft failure, and 1 case of idiopathic pneumonia syn-
drome. Five patients stopped sorafenib after the initial 28-
day DLT period because of related toxicities, which
included weight loss, tongue/facial swelling, and persistent
gastrointestinal symptomsmanifestingmainly as nausea and
diarrhea.
Of the 16 patients treated at the MTD of 400 mg BID, 4 did
not required a dose reductiond3 ﬁnished all 12 cycles and 1
remains on active therapy; 6 patients required 2 dose re-
ductions to 200 mg BID, which was then much better toler-
ated; the remaining 5 patients came off therapyd1 DLT, 1
relapse, 3 because of gastrointestinal (GI) toxicity, even at the
200 mg BID dose. As shown in Table 2, the most common
toxicities observed were skin rashes and GI symptoms,
which improved with drug interruptions or dose reductions.
The majority of the skin rashes appeared clinically consistent
with acute GVHD; however, they all resolved with temporary
holding of sorafenib. There were no obvious effects of sor-
afenib on tacrolimus drug levels; however, the single patient
who was taking cyclosporine did have a signiﬁcant increase
in her level after starting sorafenib.
Four patients had acute GVHD requiring systemic therapy
before starting sorafenib, and none of these patients expe-
rienced a ﬂare of acute GVHD symptoms while on sorafenib.
Of the remaining 18 patients, only 1 patient developed acute
GVHD after starting sorafenib and this was grade II disease of
the skin treated with topical therapy. The cumulative inci-
dence of any chronic GVHD in the 12 months after starting
sorafenib was 38% (90% conﬁdence interval [CI], 21% to 56%).Outcomes
There have been 3 relapses observed thus far. Two of
these were the 2 patients with primary refractory AML who
had achieved < 5% bone marrow blasts with single-agent
sorafenib before myeloablative HSCT. The ﬁrst relapse
occurred 13 months after HSCT. This patient had taken sor-
afenib for 5 months but then discontinued therapy for the
6 months before relapse because of the development of
nephrotic syndrome. The FLT3-ITD was found to be present
at relapse and the patient died shortly thereafter. The second
relapse occurred 12months after HSCT while the patient was
still taking 200 mg BID of sorafenib. The FLT3-ITD was also
present in this case at relapse, and she died 10 months later.
The third relapse occurred in a patient whowas in CR1 before
Figure 1. PFS and OS for all patients (n ¼ 22) and for patients in CR1/CR2
(n ¼ 19).
Figure 2. (A) Plasma inhibitory activity (PIA) assay of a patient treated with
200 mg twice daily sorafenib. B indicates baseline; D, treatment day (eg, C1D8,
day 8 of cycle 1); M3, cycle 3; M6, cycle 6. (B) PIA results (expressed as percent
of phosphorylated FLT3 at baseline) plotted against plasma sorafenib levels
measured from the same time points. The color of the dot denotes the sor-
afenib dose the patient was receiving at the time of the measurement (not the
original cohort assigned). Black dots indicate 200 mg twice daily; red dots,
400 mg in the AM, 200 mg in the PM; blue dots, 400 mg twice daily. Note that
several patients had multiple samples represented at different time points.
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HSCT. FLT3-ITD was present at relapse and he remains alive
on other treatment.
There have been a total of 4 deaths. All 3 patients with
primary refractory disease before HSCT have diedd2 from
relapse described above and the other from idiopathic
pneumonia syndrome occurring about 3 months after HSCT.
The last death was in a patient who survived 15 months
after HSCT with no evidence of recurrent AML but who
developed secondary graft failure and subsequently died of
cirrhosis from secondary iron overload. Sorafenib had been
stopped for 12 months before his death because of unre-
lated cytopenias. For the entire cohort, 1-year PFS is 85%
(90% CI, 66% to 94%) and 1-year OS is 95% (90% CI, 79% to
99%), whereas 2-year PFS is 72% (90% CI, 49% to 86%) and 2-
year OS is 78% (90% CI, 51% to 91%) (Figure 1). For the 19
patients who were in a conventional complete remission
(CR1/CR2) before HSCT, 1-year PFS is 95% (90% CI, 76% to
99%) and 1-year OS is 100%, whereas 2-year PFS is 86% (90%
CI, 61% to 96%) and 2-year OS is 78% (90% CI, 51% to 91%)
(Figure 1).Correlative Studies
Serial peripheral blood samples were collected from
available patients at established time points. FLT3 inhibitory
activity was examined in a PIA using an FLT3 mutant cell line
to assess target inhibition potential ex vivo. FLT3 inhibition
was observed in patients at all dose levels tested, as shown in
Figure 2A. Inhibition of phosphorylated FLT3 to less than 15%
of baseline was observed in 25 out of 30 samples evaluated
by PIA. There was no clear correlation between effective in-
hibition and dose level (Figure 2B).
Pharmacokinetic analysis was performed on concentra-
tions of both sorafenib and its metabolite, sorafenib N-oxide.
There was no signiﬁcant correlation between concentration
of either sorafenib or sorafenib N-oxide with dose of sor-
afenib administered, and both exhibited moderate interin-
dividual variability (Figure 3). Plasma concentrations of FLT3
ligand were also measured serially in 7 patients. Median
level at baseline and before any sorafenib administrationwas
125 pg/mL (range, 40 to 323) and this signiﬁcantly increased
to a median level of 254 pg/mL (range, 80 to 500) (P ¼ .016)
on day 29 of cycle 1 (Figure 4).DISCUSSION
Sorafenib is an oral tyrosine kinase inhibitor that is FDA
approved for the treatment of metastatic hepatocellular,
thyroid, and renal cell carcinoma with inhibitory activity
demonstrated against the FLT3 tyrosine kinase. We con-
ducted a phase I trial to deﬁne the maximum tolerated dose
of sorafenib given as maintenance therapy after HSCT as
there has been very little experience using sorafenib soon
after HSCT and before relapse of AML. In addition, one pre-
vious study suggested that use of sorafenib after HSCT might
potentially trigger signiﬁcant rates of acute GVHD [23].
Although the number of patients we studied is small, our
results are compelling, showing good tolerability of sorafenib
at doses between 200 and 400 mg BID. In addition, 1-year
PFS of 85% for all patients, including several patients who
underwent transplantation beyond CR1 and many under-
going reduced-intensity HSCT. Most notably, out of the 19
patients who had achieved a conventional CR1 or CR2 before
transplantation, there has been only 1 relapse, yielding a 1-
year PFS of 95% and 2-year PFS of 86% at a median follow-
up of 16.7 months after HSCT.
Increasingly, HSCT in CR1 has become the standard
treatment for patients with FLT3-ITD AML. This is based on
the results of several retrospective analyses that have sug-
gested superior outcomes with HSCT compared with stan-
dard chemotherapy approaches [8-13]. To date, the largest
series describing the outcome of FLT3-ITD AML after HSCT is
an observational study from the European Group for Blood
and Marrow Transplantation registry that analyzed 120
Figure 3. Pharmacokinetics of sorafenib and N-oxide. Plasma concentrations of sorafenib and N-oxide were measured at several time points. Note that several
patients had multiple samples represented at different time points.
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matched related or unrelated donor HSCT. This study
demonstrated a 2-year DFS of 58%, with the majority of re-
lapses occurring in the ﬁrst year after HSCT [13]. Thus,
relapse remains the biggest obstacle to achieving long-term
survival.
Use of sorafenib around HSCT was ﬁrst reported by
Metzelder et al. in 6 patients with FLT3-ITD AML showing
that it induced meaningful and rapid responses in overt
leukemia either before or after HSCT [24]. Others have also
described case reports illustrating the ability of sorafenib to
bring about sustained remissions at relapse of FLT3-ITD AML
after HSCT [25,26]. A larger report of 16 patients by Sharma
et al., however, suggested that most responses achieved at
relapse after HSCT are transient [27]. In contrast, Metzelder
et al. published a registry analysis of 65 patients with FLT3-
ITD AML treated with sorafenib at 23 centers, of whom 29
had undergone prior HSCT. Findings showed that patients
with prior HSCT developed sorafenib resistance less
frequently and at a later time relative to patients without
prior HSCT. Additionally, cases of sustained remission were
seen exclusively in those who had previously undergone
HSCT [28].
The optimal time to deliver sorafenib or other FLT3 in-
hibitors for patients with FLT3-ITD AML is unclear. Recently,
several clinical trials have incorporated sorafenib in combi-
nation with conventional chemotherapy [17,29-31], yet noneFigure 4. Plasma levels of FLT3 ligand in patients treated with sorafenib
(P ¼ .016 comparing baseline to day 28 levels).have shown any clear beneﬁt with the addition of sorafenib.
Administering sorafenib in the maintenance setting rather
than in combination with chemotherapy is supported by the
observation that chemotherapy-induced marrow aplasia
leads to elevated FLT3 ligand levels that may overwhelm on-
target activity of any FLT3 inhibitor [21,32]. In addition, the
observation that the only sustained remissions achieved
with sorafenib in relapsed FLT3-ITD AML have been in pa-
tients after HSCT suggest that sorafenib can potentially syn-
ergize with allo-immune effects provided by the donor graft
[28], and raise the possibility that inhibition of FLT3 is not the
only mechanism of action. For instance, direct donor T cell
activation by sorafenib was suggested in a mouse model [23]
and FLT3 ligandeinduced activation of dendritic cells [33]
may stimulate the graft-versus-leukemia effect. As shown
here, the administration of sorafenib does induce a signiﬁ-
cant increase in FLT3 ligand, although such levels are an
order of magnitude less than levels measured during in-
duction chemotherapy. Other studies have shown that the
exogenous administration of FLT3 ligand causes an increase
in proliferation of regulatory T cells, leading to inhibition of
GVHD [34]; however, the levels of FLT3 ligand described in
these studies are far greater than what was measured here.
Lastly, a variety of kinases in addition to FLT3 are inhibited by
sorafenib, and these actions could obviously be playing a role
in maintaining remission.
The use of maintenance agents after HSCT is routine with
available inhibitors of the Breakpoint Cluster Region - Abel-
son (BCR-ABL) tyrosine kinase in patients with CML or Phil-
adelphia chromosomeepositive acute lymphoblastic
leukemia, even without any prospective trials showing a
clear beneﬁt to such a strategy [37,38]. There is, however,
clear evidence in patients with CML indicating that intro-
ducing BCR-ABL inhibitors at the time of detectable minimal
residual disease after HSCT can induce long-term remissions
[39]. Thus, many practitioners routinely incorporate BCR-ABL
tyrosine kinase inhibitors into standard post-HSCT care. As
an increasing number of targeted and well-tolerated thera-
pies are developed that do not cause signiﬁcant cytopenias or
immunosuppression, the paradigm of maintenance therapy
after HSCTwill likely become increasingly popular, leading to
the need to conduct careful clinical trials to assess the efﬁ-
cacy, tolerability, and cost-effectiveness of such an approach.
The goal of this phase I study was to study the safety and
to deﬁne the maximum tolerated dose of sorafenib when
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sample size and heterogeneity of patient characteristics, yet
the inclusion of patients who are older, are in CR2, and who
received reduced-intensity conditioning regimens should
only lead to increased rates of relapse compared with other
series, such as the previously mentioned European Group for
Blood and Marrow Transplantation registry study. From our
experience, it does appear that sorafenib is safe when started
in the ﬁrst 120 days after HSCT. One previous report had
cautioned against potentially inducing GVHD based on a
mouse model [23], but we observed no episodes of signiﬁ-
cant acute GVHD after starting sorafenib and a comparable
incidence of chronic GVHD relative to our historical experi-
ence (20% to 40%). Upon starting sorafenib therapy, several
patients experienced an erythematous skin rash that
resembled acute GVHD clinically; however, the majority of
such rashes resolved when sorafenib was temporarily held.
Drug interruptions and dose reductions were common and
mostly due to skin and GI toxicities, similar to side effects
attributed to sorafenib in other clinical studies. Unfortu-
nately, initial AML samples were not available for analysis.
We, therefore, lack information on the FLT3-ITD allelic ratio
at diagnosis, which some have demonstrated to be prog-
nostically important [40,41]. However, it should be noted
that there is currently no standardized manner by which to
measure the allelic ratio [5], and, thus, incorporating this into
future trials may not be feasible.
In conclusion, maintenance therapy with sorafenib after
allogeneic HSCT for patients with FLT3-ITD AML is safe and
feasible. The maximum tolerated dose was found to be
400 mg twice daily, although drug interruptions and dose
reductions were common and FLT3 inhibition appeared to be
as effective at the 200mg twice daily dose as well, which was
better tolerated. Our rates of PFS and OS compare favorably
with historical experience. This is especially the case for
patients in a conventional complete remission before HSCT,
where only 1 of 19 cases has relapsed. Maintenance therapy
with sorafenib after HSCT for patients with FLT3-ITD AML
merits further study, and a large multicenter study is
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